DOCSLIB.ORG

Design and Synthesis of 5-HT1A Receptor Ligands

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Design and Synthesis of 5-HT1A Receptor Ligands Design and Synthesis of 5-HT ia Receptor Ligands A thesis presented to the University of London in partial fulfilment of the requirements for the degree of Doctor of Philosophy by Kit Yee Wong University College London Chemistry Department Christopher Ingold Laboratories 20 Gordon Street London WC1H OAJ April 1997 Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it, is understood to recognise that the copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author. ProQuest Number: 10017478 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10017478 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 To My Parents Abstract Serotonin (5-hydroxytryptamine, 5-HT) is a biogenic amine known to function through a number of different 5-HT receptor subtypes. The 5 -HT ia receptor subtype is implicated in conditions such as depression and anxiety. There are many examples of selective agonists for this receptor, although selective antagonists have only recently become available. Aryloxyalkylamine p- adrenergic antagonists, such as pindolol and propranolol, are one of the few classes of ligands that exhibit antagonist activity at 5 -HT ia receptors, although they are not selective. This thesis describes the synthesis and biological activity of a series of pindolol and propranolol analogues, with the aim of improving their 5 -H T ia receptor affinities and selectivities. Modifications to the terminal amine substituents of these compounds were made and the effect of 7-substitution in the naphthalene ring was explored. These analogues possess high 5-H T ia versus p-adrenergic receptor selectivities, although few compounds show significant 5-H T ia versus 5-HTi o receptor selectivity. In particular, the 7 -CONH2 and 7-C02M e substituted N,N- ethylbutylaminoethoxynaphthalenes were found to be potent agonists at the 5-HT-|a receptor, having IC50 values of 3.3 and 5.2 nM respectively. Substitution of different groups in the 7-position of the naphthalene ring was found to have a profound effect on the 5 -HT i a and 5-HT i d receptor affinities. Using the Hansch linear-free energy model, attempts were made to determine the relationships between the physicochemical nature of the substituents and their biological activities at these receptors. A multiple least squares linear regression procedure was used to generate several QSAR models. The models were analysed by statistical procedures to determine their validity and significance. Although the procedure did not yield a valid model for the 5 -HT ia receptor affinities, good correlations were obtained for the 5 -HT id receptor affinities. Acknowledgements I wish to thank my supervisor, Professor Robin Ganellin for giving me the opportunity to work on this project. I am extremely grateful for his constant support and encouragement throughout the course of this work. Thanks to Mr Wasyl Tertiuk and all the members of the group, past and present for their friendship and helpful discussions. To all my friends in the Chemistry Department, past and present, who have made the whole experience so enjoyable. Special thanks are due to Ashley (manager of the mini-cluster), Nicola, Tiz, Zena, Najeeb, Simon, Rodney, Stefan and Alvin for all the good times over the last three years. I am indebted to Dr Margaret Beer and her team at Merck Sharp and Dohme (Harlow) for carrying out the 5 -HT ia and 5-HT-| d receptor binding assays, and for organising the p-adrenergic receptor assays. I am extremely grateful for her endless patience, friendship and encouraging e-mails during the course of this study. I would like to express my gratitude to all the technical staff - Steve Corker, John Hill, Jill Maxwell, Don Shipp (Birkbeck), and Alan Stones for their efficient services. Thanks also to Chris Cooksey for his assistance with the NMR experiments, to Dr Derek Banthorpe for his entertaining and thought-provoking discussions and to Dr Mike Abraham for his helpful suggestions. Thanks to Peter Leighton for looking after (!) my overnight experiments. I would also like to thank Dr Clare Stanford for giving me the opportunity to undertake some pharmacological binding assays at UCL Pharmacology Department, and for her invaluable discussions. Thanks to Ming for the loan of his computer in the first two years and for buying and installing the memory into my own computer. Thanks to Kit Junior for all the letters and phone calls during the writing-up period. Finally I am indebted to my mum and dad for their love, encouragement and support throughout my life, and it is to them that I dedicate this thesis. Contents Abstract 3 Acknowledgements 4 Contents 5 Glossary 9 1. Introduction 10 1.1 Discovery of Serotonin 10 1.2 Distribution of 5-HT 10 1.3 Biosynthesis and Catabolism of 5-HT 11 1.4 5-HT Receptors 11 1.4.1 Historical 11 1.4.2 Cloning of 5-HT Receptors 13 1.4.3 Structure of 5-HT Receptors 13 1.5 Present Classification of 5-HT Receptors 14 1.5.1 5-HT-i Receptors 15 1.5.2 5 -HT2 Receptors 21 1.5.3 5 -HT3 Receptor 24 1.5.4 5 -HT4 Receptor 25 1.5.5 5-hts Receptors 27 1.5.6 5-hte Receptor 27 1.5.7 5-hty Receptor 28 1.6 The 5 -HT1A Receptor 28 1.6.1 Molecular Biology 28 1.6.2 5 -HT1A Receptor Distribution and Function 29 1.6.3 Structure of the 5 -HT ia Receptor 29 1.6.4 5-HTiA Receptor Ligands 30 1.7 Aryloxyalkylamines as 5-HTi a Receptor Ligands 35 1.8 Structure-Activity Analysis 35 1.8.1 Benzyloxypropanoiamines 36 1.8.2 Pindolol Derivatives 38 1.8.3 Propranolol Derivatives 42 2. Selection of Compounds 47 2.1 Project Aims 47 2.2 Pindolol Series 47 2.3 Propranolol Series 49 3. Synthesis of Aryloxyalkylamines 53 3.1 Synthetic Strategy for Unsubstituted Indolyloxyalkylamines 53 3.1.1 Synthesis of 4-Hydroxyindole 54 3.1.2 Synthesis of Side Chain Intermediates 56 3.1.3 Synthesis of Target Pindolol Derivatives 57 3.2 Attempted Synthesis of 2-Substituted Pindolol Analogues 58 3.3 Synthesis of Propranolol Analogues 61 3.4 Synthetic Strategy for Type A Compounds 63 3.4.1 Synthesis of 4-Acetylphenylbutanoic acid 65 3.4.2 Oxidation of 4-Acetylphenylbutanoic acid 67 3.4.3 Cyclisation of 4-Carboxyphenylbutanoic acid 69 3.4.4 Dehydrogenation of 7-Carboxymethyl-1-tetralone 71 3.4.5 Formation of Aminoalkyl Side Chain Propranolol Analogues 75 3.4.6 Derivatisation of the Ester Function of UCL 1693 79 3.4.7 Formation of 7-Carboxymethyl-Propranolol 83 3.5 Synthetic Strategy for Type B Compounds 86 3.5.1 Friedel-Crafts Acylation of Substituted Benzenes 88 3.5.2 Clemmensen Reduction of Keto Acids 89 3.5.3 Synthesis of Substituted Tetralones (X = Me, 'Pr, OMe, F) 90 3.5.4 Synthesis of 7-Chloro-1-tetralone 90 3.5.5 Formation of 7-Substituted-1-naphthols (X = Me, 'Pr, OMe, F) 91 3.5.6 Synthesis of 7-Chloro-1-naphthol 93 3.5.7 Formation of Target 1,7-Naphthalene Compounds 97 4. Pharmacological Methods 100 4.1 Receptor-Ligand Interactions 100 4.2 Radioligand Binding Studies 102 4.3 Functional Studies 103 4.4 Pharmacological Protocols 104 5. Pharmacological Results and Discussion 109 5.1 Indolyloxyalkylamine Analogues 109 5.1.1 5-HT 1A Receptor Binding and Functional Studies 109 5.1.2 5-HT 1A versus 5-HTi q Receptor Selectivity 111 5.1.3 p-Adrenergic Receptor Binding 112 5.1.4 Summary 113 5.2 Naphthyloxyalkylamine Analogues 113 5.2.1 5-HT ia Receptor Binding and Functional Studies 113 5.2.2 5-HT 1A versus 5-HT-| d Receptor Selectivity 119 5.2.3 p-Adrenergic Receptor Binding 122 5.2.4 Summary 126 5.2.5 Functional Activity of Propranolol Derivatives 127 5.3 QSAR Studies 129 5.3.1 Introduction 129 5.3.2 Hansch Linear Free-Energy Model 130 5.3.3 QSAR Procedure 133 5.3.4 Limitations of QSAR Studies 136 5.3.5 Regression Procedure 137 5.3.6 Experimental 138 5.3.7 Results 139 5.4 Conclusion and Future Perspectives 144 6. Experimental 147 References 216 Appendix - Selected NMR Spectra 226 Glossary agonist a drug that can interact with receptors and initiate a drug response antagonist a drug that opposes the effect of another by physiological or chemical action, or by a competitive mechanism for the same receptor sites a str (IR) asymmetric stretch br s broad singlet CDCI3 deuterated chloroform CD3OD deuterated methanol d doublet dd doublet of doublets ddd doublet of doublets of doublets dg-DMSO deuterated dimethylsulfoxide, (CD 3 )2 SO dt doublet of triplets HPLC high performance liquid chromatography IC50 median inhibitory constant (concentration at which an antagonist exerts its half maximal effect) IR infrared Ki inhibitory constant calculated from experimentally obtained IC 50 values using the Cheng-Prusoff equation, Kj = IC 5 o/(1 + L/Kq) (L = final concentration of radioligand; Kq = radioligand equilibrium dissociation constant) m(IR) medium absorption m (NMR) multiplet MS mass spectrum NMR nuclear magnetic resonance NOE nuclear Overhauser enhancement q quartet QSAR quantitative structure-activity relationship quint quintet s(IR) strong absorption s (NMR) singlet sept septet s str (IR) symmetric stretch t triplet ‘t’ pseudotriplet td triplet of doublets w(IR) weak absorption Introduction 1.
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • Organic Chemistry
    Wisebridge Learning Systems Organic Chemistry Reaction Mechanisms Pocket-Book WLS www.wisebridgelearning.com © 2006 J S Wetzel LEARNING STRATEGIES CONTENTS ● The key to building intuition is to develop the habit ALKANES of asking how each particular mechanism reflects Thermal Cracking - Pyrolysis . 1 general principles. Look for the concepts behind Combustion . 1 the chemistry to make organic chemistry more co- Free Radical Halogenation. 2 herent and rewarding. ALKENES Electrophilic Addition of HX to Alkenes . 3 ● Acid Catalyzed Hydration of Alkenes . 4 Exothermic reactions tend to follow pathways Electrophilic Addition of Halogens to Alkenes . 5 where like charges can separate or where un- Halohydrin Formation . 6 like charges can come together. When reading Free Radical Addition of HX to Alkenes . 7 organic chemistry mechanisms, keep the elec- Catalytic Hydrogenation of Alkenes. 8 tronegativities of the elements and their valence Oxidation of Alkenes to Vicinal Diols. 9 electron configurations always in your mind. Try Oxidative Cleavage of Alkenes . 10 to nterpret electron movement in terms of energy Ozonolysis of Alkenes . 10 Allylic Halogenation . 11 to make the reactions easier to understand and Oxymercuration-Demercuration . 13 remember. Hydroboration of Alkenes . 14 ALKYNES ● For MCAT preparation, pay special attention to Electrophilic Addition of HX to Alkynes . 15 Hydration of Alkynes. 15 reactions where the product hinges on regio- Free Radical Addition of HX to Alkynes . 16 and stereo-selectivity and reactions involving Electrophilic Halogenation of Alkynes. 16 resonant intermediates, which are special favor- Hydroboration of Alkynes . 17 ites of the test-writers. Catalytic Hydrogenation of Alkynes. 17 Reduction of Alkynes with Alkali Metal/Ammonia . 18 Formation and Use of Acetylide Anion Nucleophiles .
    [Show full text]
  • Packet of Wiser Reports on Acetone Acetonitrile
    Ac&tone ^Hazmat - NFPA Hazard Classification Page 1 of Acetone CAS RN: 67-64-1 Hazmat - NFPA Hazard Classification SOMS DocID 2085807 Health: 1 (Slight) Materials that, on exposure, would cause significant irritation, but only minor residual injury, including those requiring the use of an approved air-purifying respirator. These materials are only slightly hazardous to health and only breathing protection is needed. Flammability: 3 (Severe) rhis degree includes Class IB and 1C flammable liquids and materials that can be easily ignited under almost all normal temperature conditions. Water may be ineffective in controlling or extinguishing fires in such materials. Instability: 0 (Minimal) This degree includes materials that are normally stable, even under fire exposure conditions, and that do not react with water.- Norma lire fighting procedures may be used. Printed by WISER for Windows (v2.3.231, database v2.108) HHS/NIH, National Library of Medicine AR000018 iile://C:\Documents and Settings\Gham\Application Data\National Library of Medicine\WISER\2.3.231.628... 9/27/20 Acetone ^Key Info Page 1 of Acetone CAS RN: 67-64-1 Key Info FLAMMABLE LIQUIDS (Polar / Water-Miscible) • HIGHLY FLAMMABLE: Easily ignited by heat, sparks or flames • CAUTION: Very low flash point; use of water spray when fighting fire may be inefficient Printed by WISER for Windows (v2.3.231, database v2.108) HHS/NIH, National Library of Medicine AR000019 file://C:\Documents and Settings\Gham\Application Data\National Library of Medicine\WISER\2.3.231.628../ 9/27/20 Acetone - -Hazmat - Explosive Limits / Potential Page 1 of Acetone CAS RIM: 67-64-1 Hazmat - Explosive Limits / Potential Highly flammable liquid.
    [Show full text]
  • Chloroform 18.08.2020.Pdf
    Chloroform Chloroform, or trichloromethane, is an organic compound with formula CHCl3. It is a colorless, sweet-smelling, dense liquid that is produced on a large scale as a precursor to PTFE. It is also a precursor to various refrigerants. It is one of the four chloromethanes and a trihalomethane. It is a powerful anesthetic, euphoriant, anxiolytic and sedative when inhaled or ingested. Formula: CHCl₃ IUPAC ID: Trichloromethane Molar mass: 119.38 g/mol Boiling point: 61.2 °C Density: 1.49 g/cm³ Melting point: -63.5 °C The molecule adopts a tetrahedral molecular geometry with C3v symmetry. Chloroform volatilizes readily from soil and surface water and undergoes degradation in air to produce phosgene, dichloromethane, formyl chloride, carbon monoxide, carbon dioxide, and hydrogen chloride. Its half-life in air ranges from 55 to 620 days. Biodegradation in water and soil is slow. Chloroform does not significantly bioaccumulate in aquatic organisms. Production:- In industry production, chloroform is produced by heating a mixture of chlorine and either chloromethane (CH3Cl) or methane (CH4). At 400–500 °C, a free radical halogenation occurs, converting these precursors to progressively more chlorinated compounds: CH4 + Cl2 → CH3Cl + HCl CH3Cl + Cl2 → CH2Cl2 + HCl CH2Cl2 + Cl2 → CHCl3 + HCl Chloroform undergoes further chlorination to yield carbon tetrachloride (CCl4): CHCl3 + Cl2 → CCl4 + HCl The output of this process is a mixture of the four chloromethanes (chloromethane, dichloromethane, chloroform, and carbon tetrachloride), which can then be separated by distillation. Chloroform may also be produced on a small scale via the haloform reaction between acetone and sodium hypochlorite: 3 NaClO + (CH3)2CO → CHCl3 + 2 NaOH + CH3COONa Deuterochloroform[ Deuterated chloroform is an isotopologue of chloroform with a single deuterium atom.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Epidemiology of Depressive Disorders 21 Aetiology 22 Treatment of Depressive Disorders 40 Prognosis 51
    The assessment of serotonin function in major depression MD Thesis William Richard Whale 2005 1 UMI Number: U201052 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U201052 Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Major depression is a common psychiatric disorder with considerable associated morbidity and mortality. Investigations to understand the causes of depression and how it can be more effectively treated are high priority. The serotonergic system has been implicated in the aetiology and treatment of depression by a wealth of preclinical and clinical evidence. This includes findings that drugs increasing serotonin neurotransmission have antidepressant action and inhibition of serotonin synthesis (via tryptophan depletion) can induce relapse of symptoms in depressed patients. Neuroendocrine challenges are an established method of indirectly examining brain serotonergic function, utilising changes in the secretion of pituitary hormones influenced by tonic serotonergic activity at the level of the hypothalamus. This thesis describes the development of two such neuroendocrine challenge tests, using the selective serotonergic probes, zolmitriptan and citalopram. Orally administered zolmitriptan, licensed for the treatment of migraine, clearly elevated plasma growth hormone in healthy subjects.
    [Show full text]
  • The Role of the Serotonergic System and the Effects of Antidepressants During Brain Development Examined Using in Vivo Pet Imaging and in Vitro Receptor Binding
    From THE DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden THE ROLE OF THE SEROTONERGIC SYSTEM AND THE EFFECTS OF ANTIDEPRESSANTS DURING BRAIN DEVELOPMENT EXAMINED USING IN VIVO PET IMAGING AND IN VITRO RECEPTOR BINDING Stal Saurav Shrestha Stockholm 2014 Cover Illustration: Voxel-wise analysis of the whole monkey brain using the PET radioligand, [11C]DASB showing persistent serotonin transporter upregulation even after more than 1.5 years of fluoxetine discontinuation. All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice-AB © Stal Saurav Shrestha, 2014 ISBN 978-91-7549-522-4 Serotonergic System and Antidepressants During Brain Development To my family Amaze yourself ! Stal Saurav Shrestha, 2014 The Department of Clinical Neuroscience The role of the serotonergic system and the effects of antidepressants during brain development examined using in vivo PET imaging and in vitro receptor binding AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM föreläsningssalen L8:00, Karolinska Universitetssjukhuset, Solna THESIS FOR DOCTORAL DEGREE (PhD) Stal Saurav Shrestha Date: March 31, 2014 (Monday); Time: 10 AM Venue: Center for Molecular Medicine Lecture Hall Floor 1, Karolinska Hospital, Solna Principal Supervisor: Opponent: Robert B. Innis, MD, PhD Klaus-Peter Lesch, MD, PhD National Institutes of Health University of Würzburg Department of NIMH Department
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • Electrocatalytic Oxidation of Cyclic Ketones the Reactions on Electrodes, Which Take Place During the Process, Are Usual for the Mediatory System Nai - M
    Electrocatalytic Oxidation of Cyclic Ketones The reactions on electrodes, which take place during the process, are usual for the mediatory system NaI - M. N. Elinson*, S. K. Feducovich, NaOH in methanol and lead to the formation of iodine or A. S. Dorofeev, G. I. Nikishin bromine at the anode and methoxide anions at the N .D. Zelinsky Institute of Organic Chemistry, cathode. Leninsky prospekt 47, 119991 Moscow B-334, Russia Then a-monohalogenation of the enol form of The oxidation of ketones is a way for preparing the ketone takes place. carboxylic acids and their derivatives, bifunctional In the presence of methoxide anions there is an equilibrium between the two possible isomers of compounds such as a-hydroxyketones, diketones and other useful intermediates in organic synthesis. a-halogenoketone 3 posessing either an axial or The formation of adipic acid from cyclohexanone is an equatorial halogen. an important industrial process. a-Halogenoketone 3 thus formed, undergoes reversible The advance of electrooxidation procedures has methoxy anion attack on the carbonyl group with a further provided organic chemists with a synthetic device of intramolecular nucleophilic substitution of the halogen great promise. But in the case of the electrooxidation of and subsequent cyclization to form epoxide 4. O- ketones only some reactions which could provide R O + MeO- R product-selectivity are known. OMe Hal Hal The first attempts of the electrochemical oxidation of 3 A ketones resulted in the formation of a mixture of acids, - OMe O(a ) OMe(e) OMe OMe(e) saturated and unsaturated hydrocarbons, carbon monoxide O MeO- 1 OH and dioxide.
    [Show full text]
  • Electrochemical Haloform Reaction Efficient Transformation of Methyl Ketones to Carboxylates
    J. Jpn. Oil Chem. Soc. Vol. 45, No. 2 (1996) 147 ORIGINAL Electrochemical Haloform Reaction Efficient Transformation of Methyl Ketones to Carboxylates Yoshiharu MATSUBARA * 1, Kazuo FUJIMOTO * 1, Hirofumi MAEKAWA * 2 and Ikuzo NISHIGUCHI * 2 * 1 Department of Applied Chemistry, Faculty of Science and Engineering, Kinki University (3-4-1 Kowakae, Higashi-Osaka-shi, Osaka-fu, •§ 577) * 2 Osaka Municipal Technical Research Institute (6-50, 1-Chome, Morinomiya, Jyoto-ku, Osaka-shi, •§ 536) Abstract : Electrolysis of aliphatic, aromatic, and ƒ¿,ƒÀ-unsaturated methyl ketones in an anhydrous alcohol containing sodium or lithium bromide using an undivided cell equipped with carbon rods as the anode and the cathode brought about electrochemical Haloform reaction to give the corresponding car- boxylates in good to excellent yields. The reaction was found to be mediated with bromonium ion, gen- erated by anodic oxidation of bromide ion. Absence of bromoform in the product mixtures of this reac- tion may be attributed to ready reduction of bromoform to highly volatile compounds, which may pro- vide high simplicity of reaction procedure. Facile and efficient introduction of carboalkoxyl groups to aromatic rings and olefinic bonds was ac- complished in two steps through initial Friedel-Crafts acetylation followed by the present electrochemi- cal method. Key words : mediator, methyl ketones, electrolysis, bromonium ion, carboxylates 1 Introduction Haloform reaction has been well known as a method for transformation of methyl ketones to the corresponding carboxylic acids using an aqueous hypohalite solution1) . Synthetic utili- ty of this reaction, however, has been considerably limited owing to use of large amounts of a hazardous halogen and a strong base, troublesome procedure such as separation and pu- rification of the desired carboxylic acid from the resulting haloform, and unsatisfactory yield.
    [Show full text]